Page last updated: 2024-12-11
ro 24-0238
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
Ro 24-0238: PAF antagonist [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 6439060 |
| CHEMBL ID | 277245 |
| SCHEMBL ID | 9120960 |
| SCHEMBL ID | 9120974 |
| MeSH ID | M0197860 |
Synonyms (22)
| Synonym |
|---|
| ro-24-0238 |
| CHEMBL277245 , |
| SCHEMBL9120960 |
| SCHEMBL9120974 |
| (2e,4e)-5-(4-methoxy-phenyl)-deca-2,4-dienoic acid ((r)-1-methyl-4-pyridin-3-yl-butyl)-amide |
| bdbm50011671 |
| (2e,4e)-5-(4-methoxyphenyl)-n-[(2r)-5-pyridin-3-ylpentan-2-yl]deca-2,4-dienamide |
| 2,4-decadienamide,5-(4-methoxyphenyl)-n-[(1r)-1-methyl-4-(3-pyridinyl)butyl]-, (2e,4e)- |
| 5-(4-methoxyphenyl)-n-(1-methyl-4-(3-pyridinyl)butyl)-2,4-decadienamide |
| (r-(e,e))-5-(4-methoxyphenyl)-n-(1-methyl-4-(3-pyridinyl)butyl)-2,4-decadienamide |
| 120555-31-9 |
| 2,4-decadienamide, 5-(4-methoxyphenyl)-n-(1-methyl-4-(3-pyridinyl)butyl)-, (r-(e,e))- |
| ro 24-0238 |
| 7g3ui0w9y5 , |
| unii-7g3ui0w9y5 |
| HY-19084 |
| CS-6684 |
| ro-24-238 |
| ro-24-0238, (-)- |
| 2,4-decadienamide, 5-(4-methoxyphenyl)-n-((1r)-1-methyl-4-(3-pyridinyl)butyl)-, (2e,4e)- |
| (2e,4e)-5-(4-methoxyphenyl)-n-((1r)-1-methyl-4-(3-pyridinyl)butyl)-2,4-decadienamide |
| AKOS040742560 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Protein Targets (1)
Inhibition Measurements
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Platelet-activating factor receptor | Homo sapiens (human) | IC50 (µMol) | 0.0400 | 0.0003 | 0.6318 | 3.7000 | AID157738; AID59351 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
Biological Processes (29)
Molecular Functions (8)
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| lipopolysaccharide binding | Platelet-activating factor receptor | Homo sapiens (human) |
| lipopolysaccharide immune receptor activity | Platelet-activating factor receptor | Homo sapiens (human) |
| G protein-coupled receptor activity | Platelet-activating factor receptor | Homo sapiens (human) |
| platelet activating factor receptor activity | Platelet-activating factor receptor | Homo sapiens (human) |
| protein binding | Platelet-activating factor receptor | Homo sapiens (human) |
| phospholipid binding | Platelet-activating factor receptor | Homo sapiens (human) |
| mitogen-activated protein kinase binding | Platelet-activating factor receptor | Homo sapiens (human) |
| G protein-coupled purinergic nucleotide receptor activity | Platelet-activating factor receptor | Homo sapiens (human) |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
Ceullar Components (4)
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| plasma membrane | Platelet-activating factor receptor | Homo sapiens (human) |
| membrane | Platelet-activating factor receptor | Homo sapiens (human) |
| secretory granule membrane | Platelet-activating factor receptor | Homo sapiens (human) |
| tertiary granule membrane | Platelet-activating factor receptor | Homo sapiens (human) |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
Bioassays (15)
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID77001 | PAF-induced capillary permeability changes are studied in guinea pig skin test, after peroral administration of the compound | 1989 | Journal of medicinal chemistry, Aug, Volume: 32, Issue:8 | Pentadienyl carboxamide derivatives as antagonists of platelet-activating factor. |
| AID77730 | Ability to prevent PAF-induced bronchoconstriction in guinea pig when administered at a dose of 1 mg/kg intravenously | 1989 | Journal of medicinal chemistry, Aug, Volume: 32, Issue:8 | Pentadienyl carboxamide derivatives as antagonists of platelet-activating factor. |
| AID76658 | Ability to prevent PAF-induced bronchoconstriction in guinea pig when administered intravenously | 1989 | Journal of medicinal chemistry, Aug, Volume: 32, Issue:8 | Pentadienyl carboxamide derivatives as antagonists of platelet-activating factor. |
| AID76854 | Inhibition of PAF-induced bronchoconstriction in guinea pig after oral administration after two-hour pretreatment time | 1991 | Journal of medicinal chemistry, Mar, Volume: 34, Issue:3 | Triazolobenzo- and triazolothienodiazepines as potent antagonists of platelet activating factor. |
| AID77727 | Ability to prevent PAF-induced bronchoconstriction in guinea pig 2 hr after administration (50 mg/kg perorally) | 1989 | Journal of medicinal chemistry, Aug, Volume: 32, Issue:8 | Pentadienyl carboxamide derivatives as antagonists of platelet-activating factor. |
| AID183139 | PAF-induced capillary permeability changes are studied in rat skin test, after intravenous administration of the compound | 1989 | Journal of medicinal chemistry, Aug, Volume: 32, Issue:8 | Pentadienyl carboxamide derivatives as antagonists of platelet-activating factor. |
| AID76267 | Inhibition of PAF-induced bronchoconstriction in the guinea pig, (1 mg/kg) intravenously at one-minute pretreatment time | 1991 | Journal of medicinal chemistry, Mar, Volume: 34, Issue:3 | Triazolobenzo- and triazolothienodiazepines as potent antagonists of platelet activating factor. |
| AID76991 | Inhibitory activity against bronchoconstriction in guinea pig 2 hr after peroral administration of compound | 1989 | Journal of medicinal chemistry, Aug, Volume: 32, Issue:8 | Pentadienyl carboxamide derivatives as antagonists of platelet-activating factor. |
| AID183140 | PAF-induced capillary permeability changes are studied in rat skin test, after peroral administration of the compound | 1989 | Journal of medicinal chemistry, Aug, Volume: 32, Issue:8 | Pentadienyl carboxamide derivatives as antagonists of platelet-activating factor. |
| AID77728 | Ability to prevent PAF-induced bronchoconstriction in guinea pig 6 hr following 50 mg/kg p.o. administration. | 1989 | Journal of medicinal chemistry, Aug, Volume: 32, Issue:8 | Pentadienyl carboxamide derivatives as antagonists of platelet-activating factor. |
| AID77002 | PAF-induced capillary permeability changes are studied in guinea pig test, after intravenous administration of the compound | 1989 | Journal of medicinal chemistry, Aug, Volume: 32, Issue:8 | Pentadienyl carboxamide derivatives as antagonists of platelet-activating factor. |
| AID59351 | PAF-antagonist activity determined in dog platelets by PAF-binding assay | 1991 | Journal of medicinal chemistry, Mar, Volume: 34, Issue:3 | Triazolobenzo- and triazolothienodiazepines as potent antagonists of platelet activating factor. |
| AID157738 | Inhibition of [3H]PAF binding to dog platelets. | 1989 | Journal of medicinal chemistry, Aug, Volume: 32, Issue:8 | Pentadienyl carboxamide derivatives as antagonists of platelet-activating factor. |
| AID76987 | Inhibition of PAF-induced bronchoconstriction in the guinea pig after intravenous administration | 1991 | Journal of medicinal chemistry, Mar, Volume: 34, Issue:3 | Triazolobenzo- and triazolothienodiazepines as potent antagonists of platelet activating factor. |
| AID76269 | Inhibition of PAF-induced bronchoconstriction in the guinea pig after 1 mg/kg p.o. administration two hours prior to challenge. | 1991 | Journal of medicinal chemistry, Mar, Volume: 34, Issue:3 | Triazolobenzo- and triazolothienodiazepines as potent antagonists of platelet activating factor. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
Research
Studies (7)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 1 (14.29) | 18.7374 |
| 1990's | 6 (85.71) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 12.79
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.79) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 2 (28.57%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (71.43%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||